XPyto Adds Pharmaceutical Manufacturing Expert Dr. Florian A. Sahr to its European Team


VANCOUVER, BC and UTTENWEILER / ACCESSWIRE / June 8, 2022 /X Phyto Therapeutics Corp.(CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPyto” or the “Company”) is pleased to announce that Dr. Florian A. Sahr has joined its European operations as Head of Project Management. Dr. Sahr is a German-born, foreign-trained leader in drug formulation, technology transfer, and new product manufacturing.

Dr. Sahr has a strong background in drug development, including transdermal (“TDS”) and oral soluble (“ODF”) delivery systems, as well as the physical and regulatory establishment of pharmaceutical manufacturing facilities. GMP and FDA compliant. Several job highlights include his work as Senior Scientist, Head of Manufacturing, Gen-Plus GmbH & Co. KG, Munich, Germany, where he developed TDS and ODF drug formulations and transferred these new formulations and technologies to manufacturing systems and facilities; and his work as Project Manager, Advanced Projects, tesa Labtec GmbH, Langenfeld, Germany, focusing on project management and technology transfer of generic TDS formulations to company manufacturing facilities. Dr. Sahr has held the regulated position of Manufacturing Manager according to AMG/AMWHV (German Medicines Act) for the production of clinical trial material for a number of companies.

Dr. Sahr is employed full-time at Vektor Pharma TF GmbH (“Vektor”), the German subsidiary wholly owned by XPyto. Dr. Sahr’s management of Vektor’s TDS and ODF product development programs, and his skills in technology transfer are highly relevant as XPyto examines its new ODF biosensor manufacturing options and opportunities.

About XPyto Therapeutics Corp.

XPyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostics and new investment opportunities in active pharmaceutical ingredients, including: precision transdermal and oral soluble drug formulations; rapid and inexpensive diagnostic tests for infectious diseases and oral health; and the manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological disorders. The Company has research and development activities in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

X Phyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Email: info@xphyto.com
Telephone: +1 780-818-6422

Forward-looking statements

This press release contains statements that contain forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “propose” and other similar words or statements that certain events or conditions “may” or “will” occur, and in this release include the statement regarding the company’s purpose to build a successful diagnostics, drug distribution and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results differ materially from those projected in the forward-looking statements, including: that the Company may not be successful in developing a commercial product; that selling products may not be a viable business; that the Company may not be able to expand its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favorable terms; currency risks; competition; international risks; and other risks beyond the Company’s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. expressly requires. Neither the CSE nor its Market Regulator (as that term is defined in the CSE policies) accepts responsibility for the adequacy or accuracy of this press release.

THE SOURCE: X Phyto Therapeutics Corp.

See the source version on accesswire.com:


Comments are closed.